US 11,685,950 B2 · Method of diagnosing and treating acute rejection in kidney transplant patients

Abstract

Provided are a method of diagnosing the onset of acute rejection, the method including the step of correlating expression levels of one or more miRNAs selected from the group consisting of 8 kinds of miRNAs including miR-4488, miR-4532, miR-146a-5p, miR-21-5p, miR-373-3p, miR-31-5p, miR-223-3p, and miR-210-3p, and a combination thereof with the onset of acute rejection in kidney transplant patients, a composition for diagnosing acute rejection, the composition including an agent capable of measuring the expression level of each of the miRNAs, a kit for diagnosing acute rejection, the kit including the composition, and a method of treating acute rejection, the method including the step of treating acute rejection, when the onset of acute rejection is identified by the above diagnostic method. Since miR-4488, miR-4532, miR-146a-5p, miR-21-5p, miR-373-3p, miR-31-5p, miR-223-3p, and miR-210-3p according to the present invention exist in high levels in the urine of a patient with acute kidney transplant rejection, they may be used to easily diagnose the onset of acute kidney transplant rejection, thereby being used in the effective treatment of acute rejection after kidney transplantation.

Claims6

Dependent claims

A method of treating acute rejection of a kidney transplant, the method comprising the steps of:

(a) obtaining a urine sample isolated from an individual suspected of developing acute kidney transplant rejection;
(b) quantitatively analyzing expression levels of miRNAs miR-4532, miR-21-5p, and miR-31-5p in the obtained urine sample;
(c) correlating the quantitatively analyzed miRNA expression levels with the onset of acute kidney transplant rejection by applying a regression model of Equation 2:
ln
⁡
(
p
1
-
p
)
=
-
1.158
+
(
-
1.103
×
miR
⁢
4532
)
+
(
1.2
×
miR
⁢
21
)
+
(
1.16
×
miR
⁢
31
)
in which
miR4532 represents the expression level of miR-4532,
miR21 represents the expression level of miR-21-5p, and
miR31 represents the expression level of miR-31-5p;
(d) predicting that the individual has or will develop acute rejection when the result of Equation 2 is greater than 0.650;
and
(e) treating the individual, wherein the treating is performed by steroid pulse therapy, anti-T cell antibody therapy, or high-dose treatment or modulation of an immunosuppressive agent.

43 more elements

Dependencies are inferred from the claim text.

Method of diagnosing and treating acute rejection in kidney transplant patients

Life of this patent

Method of diagnosing and treating acute rejection in kidney transplant patients

Life of this patent

Abstract

Claims6